EQS-Adhoc
Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care – Additional earnings contribution of EUR 0.28 to EUR 0.34 per share expected
- Viromed Medical AG partners with CORIUS Group for exclusive cold plasma therapy
- Expected additional earnings of EUR 0.28 to EUR 0.34 per share from 2025
- Agreement allows Viromed to offer Plasma Care to 1,250,000 patients in Europe
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG concludes agreement with CORIUS Group for exclusive use of cold plasma therapy with Plasma Care by Viromed – Additional earnings contribution of EUR 0.28 to EUR 0.34
per share expected from 2025 onwards |
Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de
End of Inside Information
22-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: | English |
Company: | Viromed Medical AG |
Flensburger Straße 18 | |
25421 Pinneberg | |
Germany | |
Phone: | +49 4101 809960 |
E-mail: | kontakt@viromed-medical.de |
Internet: | https://www.viromed-medical-ag.de/ |
ISIN: | DE000A3MQR65 |
WKN: | A3MQR6 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg |
EQS News ID: | 1886029 |
End of Announcement | EQS News Service |
|
1886029 22-Apr-2024 CET/CEST